BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset TJ-CD4B, at the American Association for Cancer Research (AACR) Virtual Annual Meetin

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a clinical laboratory permit from the New York State Department of Health (NYS DOH) to provide commercial testing of KidneyIntelX™.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its fourth quarter and full year financial results for the year ended December 31, 2019 and provided a business update.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger brings to Catabasis more than 20 years of experience at commercial-stage pharmaceutical and biotechnology companies. “Ben brings to Catabasis extensive senior legal and compliance experience in the pharmaceutical industry, inc

Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation − Real-World Community-Based Trial (US MM-6) Results Show Deepening of Responses and Favorable Safety Profile in Transition from Parenteral Bortezomib to Oral NINLARO-Based Treatment − Oral Presentations Among 12 Takeda-Sponsored Abstract

Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020 . WFH is an

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the JMP Securities Virtual Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Investors sectio

Cerus Corporation (Nasdaq:CERS) celebrates World Blood Donor Day this Sunday, June 14, 2020. Enacted by the World Health Organization (WHO), World Blood Donor Day highlights the need for safe blood and safe blood products, while recognizing donors for their life-saving donations. This year’s “Safe blood saves lives” campaign calls attention to the

AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation Same AU-011 Data Will Also be Virtually Presented at the Upcoming World Ophthalmology Congress 2020 and American Society of Retinal Specialists 2020 Annual Meeting

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defect s Noveome to conduct Phase 2b trial of ST266 in Persistent Corneal Epithelial Defects